Recent Developments in SARS-CoV-2 Neutralizing Antibody Detection Methods

Abstract

The ongoing Coronavirus disease 19 pandemic has likely changed the world in ways not seen in the past. Neutralizing antibody (NAb) assays play an important role in the management of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) outbreak. Using these tools, we can assess the presence and duration of antibody-mediated protection in naturally infected individuals, screen convalescent plasma preparations for donation, test the efficacy of immunotherapy, and analyze NAb titers and persistence after vaccination to predict vaccine-induced protective effects. This review briefly summarizes the various methods used for the detection of SARS-CoV-2 NAbs and compares their advantages and disadvantages to facilitate their development and clinical application.

Keywords

Coronavirus disease 19 / severe acute respiratory syndrome coronavirus-2 / neutralizing antibodies / viral neutralization test / plaque reduction neutralization test / pseudovirus-based neutralization assays / enzyme-linked immunosorbent assay / lateral flow immunoassays

References

[1] Weekly epidemiological update on COVID-19 — 21 September 2021. Available from: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19-21-september-2021. [Accessed Sep 22, 2021].

[2] TangQ, SongY, ShiM, et al.. Inferring the hosts of coronavirus using dual statistical models based on nucleotide composition. Sci Rep, 2015, 5: 17155

[3] CuiJ, LiF, ShiZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol, 2019, 17(3): 181-192

[4] Chan-YeungM, XuRH. SARS: epidemiology. Respirology, 2003, 8: S9-S14 Suppl)

[5] Middle East respiratory syndrome coronavirus (MERS-CoV). Available from: https://www.who.int/westernpacific/health-topics/middle-east-respiratory-syndrome-coronavirus-mers. [Accessed September 13, 2021].

[6] ChanJFW, YuanS, KokKH, et al.. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet, 2020, 395(10223): 514-523

[7] KampfG, TodtD, PfaenderS, et al.. Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents. J Hosp Infect, 2020, 104(3): 246-251

[8] WuZ, McGooganJM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA, 2020, 323(13): 1239-1242

[9] YuC, LeiQ, LiW, et al.. Clinical Characteristics, Associated Factors, and Predicting COVID-19 Mortality Risk: A Retrospective Study in Wuhan, China. Am J Prev Med, 2020, 59(2): 168-175

[10] Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol, 2020, 5(4): 536-544

[11] ChenY, LiuQ, GuoD. Emerging coronaviruses: Genome structure, replication, and pathogenesis. J Med Virol, 2020, 92(10): 2249

[12] LiC, YangY, RenL. Genetic evolution analysis of 2019 novel coronavirus and coronavirus from other species. Infect Genet Evol, 2020, 82: 104285

[13] WuA, PengY, HuangB, et al.. Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China. Cell Host Microbe, 2020, 27(3): 325-328

[14] ZhuN, ZhangD, WangW, et al.. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med, 2020, 382(8): 727-733

[15] WangC, LiuZ, ChenZ, et al.. The establishment of reference sequence for SARS-CoV-2 and variation analysis. J Med Virol, 2020, 92(6): 667-674

[16] YoshimotoFK. The Proteins of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS CoV-2 or n-COV19), the Cause of COVID-19. Protein J, 2020, 39(3): 198-216

[17] ChanJFW, KokKH, ZhuZ, et al.. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect, 2020, 9(1): 221-236

[18] VashistSK. In Vitro Diagnostic Assays for COVID-19: Recent Advances and Emerging Trends. Diagnostics (Basel), 2020, 10(4): E202

[19] WrappD, WangN, CorbettKS, et al.. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science, 2020, 367(6483): 1260-1263

[20] WallsAC, ParkY-J, TortoriciMA, et al.. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell, 2020, 183(6): 1735

[21] HuangY, YangC, XuX-F, et al.. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacol Sin, 2020, 41(9): 1141-1149

[22] PremkumarL, Segovia-ChumbezB, JadiR, et al.. The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. Sci Immunol, 2020, 5(48): eabc8413

[23] DanJM, MateusJ, KatoY, et al.. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science, 2021, 371(6529): eabf4063

[24] ToKKW, TsangOTY, LeungWS, et al.. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis, 2020, 20(5): 565-574

[25] IyerAS, JonesFK, NodoushaniA, et al.. Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. Sci Immunol, 2020, 5(52): eabe0367

[26] RöltgenK, PowellAE, WirzOF, et al.. Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome. Sci Immunol, 2020, 5(54): eabe0240

[27] SeowJ, GrahamC, MerrickB, et al.. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nat Microbiol, 2020, 5(12): 1598-1607

[28] TangF, QuanY, XinZT, et al.. Lack of peripheral memory B cell responses in recovered patients with severe acute respiratory syndrome: a six-year follow-up study. J Immunol, 2011, 186(12): 7264-7268

[29] IbarrondoFJ, FulcherJA, Goodman-MezaD, et al.. Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19. N Engl J Med, 2020, 383(11): 1085-1087

[30] GudbjartssonDF, NorddahlGL, MelstedP, et al.. Humoral Immune Response to SARS-CoV-2 in Iceland. N Engl J Med, 2020, 383(18): 1724-1734

[31] RippergerTJ, UhrlaubJL, WatanabeM, et al.. Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence Communities and Reveal Durable Humoral Immunity. Immunity, 2020, 53(5): 925-933.e4

[32] HsuehPR, HuangLM, ChenPJ, et al.. Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirus. Clin Microbiol Infect, 2004, 10(12): 1062-1066

[33] HeZ, DongQ, ZhuangH, et al.. Kinetics of severe acute respiratory syndrome (SARS) coronavirus-specific antibodies in 271 laboratory-confirmed cases of SARS. Clin Diagn Lab Immunol, 2004, 11(4): 792-794

[34] ZumlaA, HuiDS, PerlmanS. Middle East respiratory syndrome. Lancet, 2015, 386(9997): 995-1007

[35] EdridgeAWD, KaczorowskaJ, HosteACR, et al.. Seasonal coronavirus protective immunity is short-lasting. Nat Med, 2020, 26(11): 1691-1693

[36] CallowKA, ParryHF, SergeantM, et al.. The time course of the immune response to experimental coronavirus infection of man. Epidemiol Infect, 1990, 105(2): 435-446

[37] ChoePG, PereraR A PM, ParkWB, et al.. MERS-CoV Antibody Responses 1 Year after Symptom Onset, South Korea, 2015. Emerg Infect Dis, 2017, 23(7): 1079-1084

[38] GasserR, CloutierM, PrévostJ, et al.. Major role of IgM in the neutralizing activity of convalescent plasma against SARS-CoV-2. Cell Rep, 2021, 34(9): 108790

[39] ZhaoJ, YuanQ, WangH, et al.. Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019. Clin Infect Dis, 2020, 71(16): 2027-2034

[40] LongQ-X, LiuBZ, DengHJ, et al.. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med, 2020, 26(6): 845-848

[41] SutharMS, ZimmermanMG, KauffmanRC, et al.. Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients. Cell Rep Med, 2020, 1(3): 100040

[42] MaH, ZengW, HeH, et al.. Serum IgA, IgM, and IgG responses in COVID-19. Cell Mol Immunol, 2020, 17(7): 773-775

[43] KellamP, BarclayW. The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection. J Gen Virol, 2020, 101(8): 791-797

[44] DuL, HeY, ZhouY, et al.. The spike protein of SARS-CoV—a target for vaccine and therapeutic development. Nat Rev Microbiol, 2009, 7(3): 226-236

[45] LiF. Structure, Function, and Evolution of Coronavirus Spike Proteins. Annu Rev Virol, 2016, 3(1): 237-261

[46] ChoH, ExclerJL, KimJH, et al.. Development of Middle East Respiratory Syndrome Coronavirus vaccines — advances and challenges. Hum Vaccin Immunother, 2018, 14(2): 304-313

[47] MatsuyamaS, NaoN, ShiratoK, et al.. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. Proc Natl Acad Sci USA, 2020, 117(13): 7001-7003

[48] ZhuZ, ChakrabortiS, HeY, et al.. Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Proc Natl Acad Sci USA, 2007, 104(29): 12123-12128

[49] RockxB, CortiD, DonaldsonE, et al.. Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge. J Virol, 2008, 82(7): 3220-3235

[50] DuL, YangY, ZhouY, et al.. MERS-CoV spike protein: a key target for antivirals. Expert Opin Ther Targets, 2017, 21(2): 131-143

[51] ZhouY, YangY, HuangJ, et al.. Advances in MERS-CoV Vaccines and Therapeutics Based on the Receptor-Binding Domain. Viruses, 2019, 11(1): E60

[52] Poh CM, Carissimo G, Wang B, et al. Potent neutralizing antibodies in the sera of convalescent COVID-19 patients are directed against conserved linear epitopes on the SARS-CoV-2 spike protein. bioRxiv, 2020:15461

[53] MeyerB, DrostenC, MüllerMA. Serological assays for emerging coronaviruses: challenges and pitfalls. Virus Res, 2014, 194: 175-183

[54] YanR, ZhangY, LiY, et al.. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science, 2020, 367(6485): 1444-1448

[55] BadenLR, El SahlyHM, EssinkB, et al.. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med, 2021, 384(5): 403-416

[56] PolackFP, ThomasSJ, KitchinN, et al.. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med, 2020, 383(27): 2603-2615

[57] LiY, MaML, LeiQ, et al.. Linear epitope landscape of the SARS-CoV-2 Spike protein constructed from 1,051 COVID-19 patients. Cell Rep, 2021, 34(13): 108 915

[58] PiccoliL, ParkYJ, TortoriciMA, et al.. Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology. Cell, 2020, 183(4): 1024-1042.e21

[59] AddetiaA, CrawfordKHD, DingensA, et al.. Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate. J Clin Microbiol, 2020, 58(11): e02107-e02120

[60] MooreJP, KlassePJ. COVID-19 Vaccines: “Warp Speed” Needs Mind Melds, Not Warped Minds. J Virol, 2020, 94(17): e01083-e01020

[61] ZoharT, AlterG. Dissecting antibody-mediated protection against SARS-CoV-2. Nat Rev Immunol, 2020, 20(7): 392-394

[62] ZostSJ, GilchukP, CaseJB, et al.. Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature, 2020, 584(7821): 443-449

[63] LeiQ, HouH, YuC, et al.. Kinetics of Neutralizing Antibody Response Underscores Clinical COVID-19 Progression. J Immunol Res, 2021, 2021: 9822706

[64] CaoY, SuB, GuoX, et al.. Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients’ B Cells. Cell, 2020, 182(1): 73-84.e16

[65] LeiQ, LiY, HouHY, et al.. Antibody dynamics to SARS-CoV-2 in asymptomatic COVID-19 infections. Allergy, 2021, 76(2): 551-561

[66] TaniH, KimuraM, TanL, et al.. Evaluation of SARS-CoV-2 neutralizing antibodies using a vesicular stomatitis virus possessing SARS-CoV-2 spike protein. Virol J, 2021, 18: 16

[67] BlochEM, ShohamS, CasadevallA, et al.. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest, 2020, 130(6): 2757-2765

[68] WölfelR, CormanVM, GuggemosW, et al.. Virological assessment of hospitalized patients with COVID-2019. Nature, 2020, 581(7809): 465-469

[69] HoffmannM, Kleine-WeberH, SchroederS, et al.. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020, 181(2): 271-280.e8

[70] OuX, LiuY, LeiX, et al.. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun, 2020, 11(1): 1620

[71] PohCM, CarissimoG, WangB, et al.. Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients. Nat Commun, 2020, 11(1): 2806

[72] TheelES, SlevP, WheelerS, et al.. The Role of Antibody Testing for SARS-CoV-2: Is There One?. J Clin Microbiol, 2020, 58(8): e00797-20

[73] LesterS, HarcourtJ, WhittM, et al.. Middle East respiratory coronavirus (MERS-CoV) spike (S) protein vesicular stomatitis virus pseudoparticle neutralization assays offer a reliable alternative to the conventional neutralization assay in human seroepidemiological studies. Access Microbiol, 2019, 1(9): e000057

[74] DegnahAA, Al-AmriSS, HassanAM, et al.. Seroprevalence of MERS-CoV in healthy adults in western Saudi Arabia, 2011–2016. J Infect Public Health, 2020, 13(5): 697-703

[75] MendozaEJ, ManguiatK, WoodH, et al.. Two Detailed Plaque Assay Protocols for the Quantification of Infectious SARS-CoV-2. Curr Protoc Microbiol, 2020, 57(1): cp-c105

[76] NiL, YeF, ChengML, et al.. Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals. Immunity, 2020, 52(6): 971-977.e3

[77] NieJ, LiQ, WuJ, et al.. Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. Emerg Microbes Infect, 2020, 9(1): 680-686

[78] CrawfordKHD, EguiaR, DingensAS, et al.. Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays. Viruses, 2020, 12(5): E513

[79] ManentiA, MaggettiM, CasaE, et al.. Evaluation of SARS-CoV-2 neutralizing antibodies using a CPE-based colorimetric live virus micro-neutralization assay in human serum samples. J Med Virol, 2020, 92(10): 2096-2104

[80] OkbaNMA, MüllerMA, LiW, et al.. Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients. Emerg Infect Dis, 2020, 26(7): 1478-1488

[81] PereraRA, MokCK, TsangOT, et al.. Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020. Euro Surveill, 2020, 25(16): 2000421

[82] XiongHL, WuYT, CaoJL, et al.. Robust neutralization assay based on SARS-CoV-2 S-protein-bearing vesicular stomatitis virus (VSV) pseudovirus and ACE2-overexpressing BHK21 cells. Emerg Microbes Infect, 2020, 9(1): 2105-2113

[83] ZettlF, MeisterTL, VollmerT, et al.. Rapid Quantification of SARS-CoV-2-Neutralizing Antibodies Using Propagation-Defective Vesicular Stomatitis Virus Pseudotypes. Vaccines (Basel), 2020, 8(3): E386

[84] SchmidtF, WeisblumY, MueckschF, et al.. Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. J Exp Med, 2020, 217(11): e20201181

[85] XieX, MuruatoAE, ZhangX, et al.. A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19. Nat Commun, 2020, 11(1): 5214

[86] FocosiD, MaggiF, MazzettiP, et al.. Viral infection neutralization tests: A focus on severe acute respiratory syndrome-coronavirus-2 with implications for convalescent plasma therapy. Rev Med Virol, 2021, 31(2): e2170

[87] RosadoJ, PelleauS, CockramC, et al.. Multiplex assays for the identification of serological signatures of SARS-CoV-2 infection: an antibody-based diagnostic and machine learning study. Lancet Microbe, 2021, 2(2): e60-e69

[88] TaylorSC, HurstB, CharltonCL, et al.. A New SARS-CoV-2 Dual-Purpose Serology Test: Highly Accurate Infection Tracing and Neutralizing Antibody Response Detection. J Clin Microbiol, 2021, 59(4): e02438-e02420

[89] MuruatoAE, Fontes-GarfiasCR, RenP, et al.. A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation. Nat Commun, 2020, 11(1): 4059

[90] TanCW, ChiaWN, QinX, et al.. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction. Nat Biotechnol, 2020, 38(9): 1073-1078

[91] ByrnesJR, ZhouXX, LuiI, et al.. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding. mSphere, 2020, 5(5): e00802-e00820

[92] FerraraF, TempertonN. Pseudotype Neutralization Assays: From Laboratory Bench to Data Analysis. Methods Protoc, 2018, 1(1): 8

[93] MukherjeeS, DowdKA, ManhartCJ, et al.. Mechanism and significance of cell type-dependent neutralization of flaviviruses. J Virol, 2014, 88(13): 7210-7220

[94] LiuL, WangP, NairMS, et al.. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature, 2020, 584(7821): 450-456

[95] PereraRA, MokCK, TsangOT, et al.. Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020. Euro Surveill, 2020, 25(16): 200421

[96] OkbaNMA, MüllerMA, LiW, et al.. Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients. Emerg Infect Dis, 2020, 26(7): 1478-1488

[97] AlgaissiA, HashemAM. Evaluation of MERS-CoV Neutralizing Antibodies in Sera Using Live Virus Microneutralization Assay. Methods Mol Biol, 2020, 2099: 107-116

[98] HaveriA, SmuraT, KuivanenS, et al.. Serological and molecular findings during SARS-CoV-2 infection: the first case study in Finland, January to February 2020. Euro Surveill, 2020, 25(11): 2000266

[99] ConteC, SogniF, AffanniP, et al.. Vaccines against Coronaviruses: The State of the Art. Vaccines (Basel), 2020, 8(2): E309

[100] GhaebiM, OsaliA, ValizadehH, et al.. Vaccine development and therapeutic design for 2019-nCoV/SARS-CoV-2: Challenges and chances. J Cell Physiol, 2020, 235(12): 9098-9109

[101] Wu F, Wang A, Liu M, et al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. medRxiv, 2020: 20047365.

[102] SprangersMC, LakhaiW, KoudstaalW, et al.. Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors. J Clin Microbiol, 2003, 41(11): 5046-5052

[103] FuX, TaoL, ZhangX. Comprehensive and systemic optimization for improving the yield of SARS-CoV-2 spike pseudotyped virus. Mol Ther Methods Clin Dev, 2021, 20: 350-356

[104] NieJ, LiQ, WuJ, et al.. Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. Emerg Microbes Infect, 2020, 9(1): 680-686

[105] TangH, KuhenKL, Wong-StaalF. Lentivirus replication and regulation. Annu Rev Genet, 1999, 33: 133-170

[106] WhitelawCBA. Transgenic livestock made easy. Trends Biotechnol, 2004, 22(4): 157-159

[107] LillicoS, VaseyD, KingT, et al.. Lentiviral transgenesis in livestock. Transgenic Res, 2011, 20(3): 441-442

[108] Picanco-CastroV, Sousa Russo-Carbolante deE, Tadeu CovasD. Advances in lentiviral vectors: a patent review. Recent Pat DNA Gene Seq, 2012, 6(2): 82-90

[109] NaldiniL. Lentiviruses as gene transfer agents for delivery to non-dividing cells. Curr Opin Biotechnol, 1998, 9(5): 457-463

[110] KumarM, KellerB, MakalouN, et al.. Systematic determination of the packaging limit of lentiviral vectors. Hum Gene Ther, 2001, 12(15): 1893-1905

[111] NaldiniL, BlömerU, GageFH, et al.. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci USA, 1996, 93(21): 11382-11388

[112] ReiserJ, HarmisonG, Kluepfel-StahlS, et al.. Transduction of nondividing cells using pseudotyped defective high-titer HIV type 1 particles. Proc Natl Acad Sci USA, 1996, 93(26): 15266-15271

[113] BlömerU, NaldiniL, KafriT, et al.. Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector. J Virol, 1997, 71(9): 6641-6649

[114] KordowerJH, BlochJ, MaSY, et al.. Lentiviral gene transfer to the nonhuman primate brain. Exp Neurol, 1999, 160(1): 1-16

[115] BleschA, TuszynskiMH. Transient growth factor delivery sustains regenerated axons after spinal cord injury. J Neurosci, 2007, 27(39): 10535-10545

[116] SinnPL, SauterSL, McCrayPB. Gene Therapy Progress and Prospects: Development of improved lentiviral and retroviral vectors — design, biosafety, and production. Gene Ther, 2005, 12(14): 1089-1098

[117] SandrinV, RussellSJ, CossetFL. Targeting retroviral and lentiviral vectors. Curr Top Microbiol Immunol, 2003, 281: 137-178

[118] CannonJR, SewT, MonteroL, et al.. Pseudotype-dependent lentiviral transduction of astrocytes or neurons in the rat substantia nigra. Exp Neurol, 2011, 228(1): 41-52

[119] CroninJ, ZhangXY, ReiserJ. Altering the Tropism of Lentiviral Vectors through Pseudotyping. Curr Gene Ther, 2005, 5(4): 387-398

[120] LewisP, HenselM, EmermanM. Human immunodeficiency virus infection of cells arrested in the cell cycle. EMBO J, 1992, 11(8): 3053-3058

[121] WangJ, DengF, YeG, et al.. Comparison of lentiviruses pseudotyped with S proteins from coronaviruses and cell tropisms of porcine coronaviruses. Virol Sin, 2016, 31(1): 49-56

[122] RenW, QuX, LiW, et al.. Difference in receptor usage between severe acute respiratory syndrome (SARS) coronavirus and SARS-like coronavirus of bat origin. J Virol, 2008, 82(4): 1899-1907

[123] KobingerGP, LimberisMP, SomanathanS, et al.. Human immunodeficiency viral vector pseudotyped with the spike envelope of severe acute respiratory syndrome coronavirus transduces human airway epithelial cells and dendritic cells. Hum Gene Ther, 2007, 18(5): 413-422

[124] NieY, WangP, ShiX, et al.. Highly infectious SARS-CoV pseudotyped virus reveals the cell tropism and its correlation with receptor expression. Biochem Biophys Res Commun, 2004, 321(4): 994-1000

[125] EscorsD, BreckpotK. Lentiviral vectors in gene therapy: their current status and future potential. Arch Immunol Ther Exp (Warsz), 2010, 58(2): 107-119

[126] NaldiniL, BlömerU, GallayP, et al.. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science, 1996, 272(5259): 263-267

[127] KimVN, MitrophanousK, KingsmanSM, et al.. Minimal requirement for a lentivirus vector based on human immunodeficiency virus type 1. J Virol, 1998, 72(1): 811-816

[128] ParolinC, DorfmanT, PalúG, et al.. Analysis in human immunodeficiency virus type 1 vectors of cis-acting sequences that affect gene transfer into human lymphocytes. J Virol, 1994, 68(6): 3888-3895

[129] FouchierRA, SimonJH, JaffeAB, et al.. Human immunodeficiency virus type 1 Vif does not influence expression or virion incorporation of gag-, pol-, and env-encoded proteins. J Virol, 1996, 70(12): 8263-8269

[130] ZuffereyR, NagyD, MandelRJ, et al.. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol, 1997, 15(9): 871-875

[131] KlaverB, BerkhoutB. Comparison of 5′ and 3′ long terminal repeat promoter function in human immunodeficiency virus. J Virol, 1994, 68(6): 3830-3840

[132] YuSF, Rüden vonT, KantoffPW, et al.. Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. Proc Natl Acad Sci USA, 1986, 83(10): 3194-3198

[133] LaspiaMF, RiceAP, MathewsMB. HIV-1 Tat protein increases transcriptional initiation and stabilizes elongation. Cell, 1989, 59(2): 283-292

[134] DullT, ZuffereyR, KellyM, et al.. A third-generation lentivirus vector with a conditional packaging system. J Virol, 1998, 72(11): 8463-8471

[135] MertenOW, HebbenM, BovolentaC. Production of lentiviral vectors. Mol Ther Methods Clin Dev, 2016, 3: 16017

[136] FragaH. Firefly luminescence: a historical perspective and recent developments. Photochem Photobiol Sci, 2008, 7(2): 146-158

[137] UckertW, PedersenL, GünzburgW. Green fluorescent protein retroviral vector: generation of high-titer producer cells and virus supernatant. Methods Mol Med, 2000, 35: 275-285

[138] HeiderS, MetznerC. Quantitative real-time single particle analysis of virions. Virology, 2014, 462–463: 199-206

[139] GeraertsM, WillemsS, BaekelandtV, et al.. Comparison of lentiviral vector titration methods. BMC Biotechnol, 2006, 6: 34

[140] CaseJB, RothlaufPW, ChenRE, et al.. Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2. Cell Host Microbe, 2020, 28(3): 475-485.e5

[141] AlmahboubSA, AlgaissiA, AlfalehMA, et al.. Evaluation of Neutralizing Antibodies Against Highly Pathogenic Coronaviruses: A Detailed Protocol for a Rapid Evaluation of Neutralizing Antibodies Using Vesicular Stomatitis Virus Pseudovirus-Based Assay. Front Microbiol, 2020, 11: 2020

[142] GanSD, PatelKR. Enzyme immunoassay and enzyme-linked immunosorbent assay. J Invest Dermatol, 2013, 133(9): e12

[143] Zhang N, Chen S, Wu J, et al. A lateral flow test detecting SARS-CoV-2 neutralizing antibodie. Available from: https://europepmc.org/article/PPR/PPR236206. 2020; [Accessed Aug 5, 2021].

[144] LequinRM. Enzyme immunoassay (EIA)/enzyme-linked immunosorbent assay (ELISA). Clin Chem, 2005, 51(12): 2415-2418

[145] Banga NdzouboukouJL, ZhangY, LeiQ, et al.. Human IgM and IgG Responses to an Inactivated SARS-CoV-2 Vaccine. Curr Med Sci, 2021, 6: 1-8Nov

[146] SchölerL, Le-TrillingVTK, EilbrechtM, et al.. A Novel In-Cell ELISA Assay Allows Rapid and Automated Quantification of SARS-CoV-2 to Analyze Neutralizing Antibodies and Antiviral Compounds. Front Immunol, 2020, 11: 573526

[147] KoczulaKM, GallottaA. Lateral flow assays. Essays Biochem, 2016, 60(1): 111-120

[148] MboowaG. Current and emerging diagnostic tests available for the novel COVID-19 global pandemic. AAS Open Res, 2020, 3: 8

[149] ParoloC, Escosura-Muñiz de laA, MerkoçiA. Enhanced lateral flow immunoassay using gold nanoparticles loaded with enzymes. Biosens Bioelectron, 2013, 40(1): 412-416

[150] XuM, WangD, WangH, et al.. COVID-19 diagnostic testing: Technology perspective. Clin Transl Med, 2020, 10(4): e158

[151] RussoA, MinichiniC, StaraceM, et al.. Current Status of Laboratory Diagnosis for COVID-19: A Narrative Review. Infect Drug Resist, 2020, 13: 2657-2665

[152] ChoudharyS, SreenivasuluK, MitraP, et al.. Role of Genetic Variants and Gene Expression in the Susceptibility and Severity of COVID-19. Ann Lab Med, 2021, 41(2): 129-138

[153] Lisboa BastosM, TavazivaG, AbidiSK, et al.. Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis. BMJ, 2020, 370: m2516

[154] YunS, RyuJH, JangJH, et al.. Comparison of SARS-CoV-2 Antibody Responses and Seroconversion in COVID-19 Patients Using Twelve Commercial Immunoassays. Ann Lab Med, 2021, 41(6): 577-587

[155] LiZ, YiY, LuoX, et al.. Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis. J Med Virol, 2020, 92(9): 1518-1524